Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29811388 | 1.00 | ATM (0.45) | ATMMEN1KMT2AHCRTR1ALDH1A1 | |
| SCHEMBL9372564 | 0.86 | ATM (0.53) | ATMMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL9712314 | 0.84 | KMT2A (0.41) | ATMMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL29811263 | 0.81 | KDM4E (0.45) | MEN1KMT2AALDH1A1KDM4EPKM | |
| SCHEMBL5525919 | 0.81 | KDM4E (0.45) | MEN1KMT2AALDH1A1KDM4EPKM | |
| SCHEMBL2384145 | 0.79 | ESR2 (0.41) | MEN1KMT2AALDH1A1TP53HPGD | |
| SCHEMBL29811590 | 0.79 | ALDH1A1 (0.37) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL607256 | 0.79 | PKM (0.44) | MEN1KMT2AHCRTR1ALDH1A1KDM4E | |
| SCHEMBL22239410 | 0.79 | PDE2A (0.46) | ALDH1A1PKMHPGDSRC | |
| SCHEMBL29811258 | 0.79 | PKM (0.44) | MEN1KMT2AHCRTR1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001874-A1 | DIHYDROQUINAZOLINONES EXHIBITING IMPROVED PROTECTIVE ACTIVITY AGAINST INTRACELLULARLY ACTING TOXINS AND INTRACELLULAR VIRUSES AND BACTERIA | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2026-01-01 | — | — | US | disclosed |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| EP-4504726-A1 | DIHYDROQUINAZOLINONES EXHIBITING IMPROVED PROTECTIVE ACTIVITY AGAINST INTRACELLULARLY ACTING TOXINS AND INTRACELLULAR VIRUSES AND BACTERIA | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2025-02-12 | — | — | EP | disclosed |
| CN-115103841-B | Substituted quinolinone piperazine compounds useful as T cell activators | 百时美施贵宝公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-4081523-B1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-4081513-B1 | SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-114901660-B | Substituted bicyclic compounds useful as T cell activators | 百时美施贵宝公司 | 2024-10-15 | — | — | CN | disclosed |
| US-12024508-B2 | Dihydroquinazolinones exhibiting protective activity against intracellular-acting toxins, intracellular viruses and bacteria | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2024-07-02 | — | — | US | disclosed |
| US-12024508-B2 | Dihydroquinazolinones exhibiting protective activity against intracellular-acting toxins, intracellular viruses and bacteria | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2024-07-02 | — | — | US | disclosed |
| EP-3886859-B1 | NEW DIHYDROQUINAZOLINONES EXHIBITING PROTECTIVE ACTIVITY AGAINST INTRACELLULAR-ACTING TOXINS, INTRACELLULAR VIRUSES AND BACTERIA | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2024-06-26 | — | — | EP | disclosed |
| US-20050176699-A1 | Benzodiazepine derivatives, preparation thereof and use thereof | ASTRAZENECA AB (SE) | 2005-08-11 | — | — | US | disclosed |
| US-20040204586-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS, INC. | 2004-10-14 | — | — | US | disclosed |
| EP-1458691-A2 | BENZODIAZEPINE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051275-A2 | BENZODIAZEPINE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051274-A2 | BENZODIAZEPINE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
| EP-0015065-B1 | PYRAZOLO (5,1-B) QUINAZOLIN-9(4H)-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WARNER-LAMBERT COMPANY (US) | 1983-12-28 | — | — | EP | disclosed |
| US-4261997-A | 4-Alkyl-pyrazolo[5,1-b]-quinazolin-9(4H)-ones and anti-allergic compositions containing them | WARNER-LAMBERT COMPANY (US) | 1981-04-14 | — | — | US | disclosed |
| EP-0015065-A1 | Pyrazolo (5,1-b) quinazolin-9(4H)-one derivatives, process for their preparation and pharmaceutical compositions containing them | WARNER-LAMBERT COMPANY (US) | 1980-09-03 | — | — | EP | disclosed |
| US-3985732-A | ANXIOLYTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
| US-3947408-A | ANTIANXIETY AGENTS | AMERICAN CYANAMID COMPANY (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024508-B2 | Dihydroquinazolinones exhibiting protective activity against intracellular-acting toxins, intracellular viruses and bacteria | STX18, STXBP1, NSF | ATM 4250/4885MEN1 2987/4885KMT2A 4585/4885 |
| US-20050176699-A1 | Benzodiazepine derivatives, preparation thereof and use thereof | GABRA1, GABRA3, GABRA4 | ATM 3521/4885MEN1 2536/4885KMT2A 1521/4885 |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | ATM 574/4885MEN1 2885/4885KMT2A 2132/4885 |
| US-20040204586-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | MIF, MSR1, MMP12 | ATM 4484/4885MEN1 1887/4885KMT2A 4043/4885 |
| US-20260001874-A1 | DIHYDROQUINAZOLINONES EXHIBITING IMPROVED PROTECTIVE ACTIVITY AGAINST INTRACELLULARLY ACTING TOXINS AND INTRACELLULAR VIRUSES AND BACTERIA | NSF, VAMP7, RAB7A | ATM 4367/4885MEN1 3584/4885KMT2A 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.